LFVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lifevantage Corp
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 27, 2026
$5.98−0.02 (-0.33%)
Close on Oct 19, 2026
- Market cap
- $74.97M
- P/E (TTM)
- 15.0
- Dividend yield
- 3.09%
Lifevantage Corp revenue by segment
By business segment
By product or service
| Revenue | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protandim product line | $81.99M | $86.03M | $89.58M | $93.19M | $95.33M | – | – | – | – | – | – | – | 44.9% | -14.0% |
| TrueScience product line | $37.85M | $39.34M | $42.14M | $45.03M | $48.71M | – | – | – | – | – | – | – | 20.7% | -22.3% |
| LifeVantage product line | $32.26M | – | – | – | $61.33M | – | – | – | – | – | – | – | 17.7% | -47.4% |
| AXIO product line | $15.01M | $15.16M | $15.62M | $15.24M | $15.31M | – | – | – | – | – | – | – | 8.2% | -2.0% |
| LoveBiome Product Line | $9.12M | – | – | – | $0 | – | – | – | – | – | – | – | 5.0% | – |
| Other | $4.40M | $5.41M | $5.94M | $5.98M | $5.73M | – | – | – | – | – | – | – | 2.4% | -23.3% |
| PhysIQ product line | $3.80M | $4.45M | $4.97M | $5.19M | $5.10M | – | – | – | – | – | – | – | 2.1% | -25.5% |
| Petandim product line | $1.96M | $1.97M | $2.05M | $2.06M | $2.12M | – | – | – | – | – | – | – | 1.1% | -7.4% |
By region
| Revenue | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $135.40M | $145.79M | $159.75M | $178.39M | $178.44M | $173.31M | $162.21M | $144.05M | $145.68M | $147.49M | $150.01M | $150.76M | 74.2% | -24.1% |
| Non-US | $47.18M | $49.54M | $50.30M | $50.49M | $50.09M | – | – | – | – | – | – | – | 25.8% | -5.8% |
| Japan | $24.15M | $24.98M | $25.60M | $25.60M | $25.39M | $24.44M | $24.42M | $25.46M | $26.99M | $29.47M | $31.38M | $31.43M | 13.2% | -4.9% |
| Other foreign markets | $23.03M | $24.56M | $24.70M | $24.88M | $24.69M | – | – | – | – | – | – | – | 12.6% | -6.7% |
| Americas | – | – | – | – | – | $180.36M | $169.37M | $151.28M | $152.91M | $154.55M | $156.87M | $157.51M | – | – |
| Asia/Pacific & Europe | – | – | – | – | – | $41.99M | $42.78M | $44.73M | $47.26M | $50.91M | $54.08M | $55.48M | – | – |
From the segment and revenue-disaggregation notes of Lifevantage's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.